Is PT-141 legal in Australia?

The short answer

PT-141, the common research name for the compound bremelanotide, is treated in Australia as a prescription-controlled substance rather than a freely available product. Public reference sources and TGA scheduling history indicate bremelanotide has been captured at the Schedule 4 (Prescription Only Medicine) level under the Poisons Standard. At the same time, there is no finished bremelanotide product entered on the Australian Register of Therapeutic Goods (ARTG) for general supply.

In practical terms, that means PT-141 is not an over-the-counter or openly sold consumer product in Australia. Where it appears in the Australian market, it is supplied as a research chemical for laboratory use only, not as an approved medicine for human use. Scheduling and registration positions can change, so the current Poisons Standard and the ARTG should always be checked directly.

How the TGA classifies PT-141

In Australia, the way a substance can be legally supplied is governed largely by the Poisons Standard, formally the Standard for the Uniform Scheduling of Medicines and Poisons (the SUSMP). The Poisons Standard sorts substances into schedules that determine how, and by whom, they may be accessed. The Therapeutic Goods Administration (TGA) administers this framework.

Schedule 4 is the Prescription Only Medicine category. Public references and TGA scheduling history place bremelanotide within Schedule 4, meaning it has been treated as a substance that, for human use, would require a prescription and a lawful supply pathway rather than open retail sale.

It is worth being precise here. A schedule classification describes how a substance is controlled for supply. It is not the same thing as having an approved, registered product on the market. Those are two separate questions, and PT-141 illustrates the gap between them.

Two separate questions

• Scheduling: what level of control applies to the substance under the Poisons Standard.
• Registration: whether a specific finished product is entered on the ARTG and approved for supply.
• Both must be understood together to describe a compound's position accurately.

Not approved: the ARTG position

The ARTG is the register of therapeutic goods that may lawfully be supplied in Australia. For a medicine to be marketed here for human use, a sponsor generally must hold an entry on the ARTG following TGA evaluation.

Based on available public information, no bremelanotide product holds an ARTG entry for general supply in Australia. The branded overseas autoinjector product is not listed on the ARTG and is not available through standard Australian channels.

The absence of an ARTG entry is significant. It means there is no TGA-evaluated, approved finished PT-141 product on the Australian market. Any PT-141 material available domestically therefore sits outside the approved-medicine framework and is appropriately described as a research compound only.

Research compound versus approved medicine

It helps to separate two very different things that share the same chemical name. One is an approved, registered medicine evaluated by a regulator for a defined purpose. The other is a research compound supplied to laboratories and researchers for investigational and analytical work, with no approval for human use.

PT-141 as sold in the Australian research market falls into the second category. It is offered research use only. That framing is not a marketing flourish. It reflects the regulatory reality that the compound is not an approved medicine here and is not supplied for consumption, self-administration or any human application.

The overseas context

Internationally, bremelanotide has a regulatory history worth noting in neutral terms. In the United States, the Food and Drug Administration approved a bremelanotide product, marketed under a brand name, on 21 June 2019. That approval was specific to the United States market and to the terms the FDA set.

An approval in one country does not carry across to Australia. Based on available public information, no bremelanotide marketing application has been approved by the Therapeutic Goods Administration, and the overseas branded product is not on the ARTG. The Australian and United States positions are distinct and should not be conflated.

A regulatory approval in one jurisdiction describes that jurisdiction only. It does not establish approval, availability or legality anywhere else.

What PT-141 is, in neutral research terms

In purely descriptive terms, PT-141 (bremelanotide) is a synthetic peptide that acts as a melanocortin receptor agonist. The melanocortin system is a family of receptors studied across a range of physiological research areas. Describing a compound's receptor target is a factual, mechanistic statement and is distinct from any claim about effects in people.

This article intentionally does not discuss dosing, administration, outcomes or any application in humans. Those topics sit outside a research-use-only and regulatory context, and nothing here should be read as guidance toward human use.

Neutral descriptors only

• Common research name: PT-141.
• Compound name: bremelanotide.
• Class: synthetic peptide.
• Described target: melanocortin receptor agonist.

A note on sport and anti-doping

Athletes and support staff bound by anti-doping rules should be aware that the World Anti-Doping Agency (WADA) Prohibited List includes broad categories that can capture peptide and peptide-hormone-type substances, including by their mechanism, even where a specific compound is not named individually.

Because the Prohibited List is updated and because category language can be interpreted broadly, anyone subject to testing in Australia should verify current status directly with Sport Integrity Australia or their sporting body before assuming anything about a given substance. This is general information, not an anti-doping clearance.

Supply in Australia and what research use only means

Given the position above, PT-141 is not an openly marketed consumer product in Australia. Where NovaPeptides references PT-141, it is as a research compound supplied strictly for laboratory and investigational purposes, not for human or veterinary use, and not for consumption of any kind.

Research use only is a meaningful designation. It signals that the material is intended for qualified research settings, that it is not an approved medicine, that no therapeutic or performance outcome is claimed, and that it must not be self-administered. Buyers are responsible for understanding and complying with the laws that apply to them, including the current Poisons Standard and import rules.

What research use only means in practice

• For laboratory and research purposes only, never for human or animal consumption.
• Not an approved medicine and not a substitute for one.
• No therapeutic, performance or efficacy outcome is claimed or implied.
• The purchaser is responsible for compliance with all applicable Australian laws.

Frequently asked questions